# AstraZeneca PLC Farxiga met primary endpoint in landmark Phase III

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-farxiga-met-primary-endpoint-in-landmark-phase-iii/412790741
- Published: 2019-08-20T07:14:28+01:00
- Author: Giles Arbor

Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment
of patients with heart failure

DAPA-HF is the first heart failure outcomes trial with an SGLT2 inhibitor in patients
with and without type-2 diabetes

Farxiga significantly reduced the risk of cardiovascular death or worsening of heart
failure when added to standard of care

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON: AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
has today announced positive results from the landmark Phase III DAPA-HF trial which
showed that Farxiga (dapagliflozin) met the primary composite endpoint with a statistically-
significant and clinically-meaningful reduction of cardiovascular death or the worsening
of heart failure (defined as hospitalisation or an urgent heart failure visit), 
compared to placebo. The trial was conducted in patients with reduced ejection fraction(
HFrEF) on standard of care treatment, including those with and without type-2 diabetes.

The safety profile of Farxiga in the DAPA-HF trial was consistent with the well-
established safety profile of the medicine.

**Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: **

> “With the DAPA-HF trial, Farxiga becomes the first in its class to demonstrate
> efficacy and safety data for the treatment of patients with heart failure, with
> and without type-2 diabetes, on top of standard of care. Today, half of heart 
> failure patients will die within five years of diagnosis and it remains one of
> the leading causes of hospitalisation. We look forward to discussing the results
> of DAPA-HF with health authorities as soon as possible.”

**John McMurray, MD, University of Glasgow, Cardiovascular Research Centre, Institute
of Cardiovascular and Medical Sciences said: **

> “The benefits of dapagliflozin in DAPA-HF are very impressive, with a substantial
> reduction in the primary composite outcome of cardiovascular death or hospital
> admission. We hope these exciting new findings will ultimately help reduce the
> terrible burden of disease caused by heart failure and help improve outcomes for
> our patients.”

DAPA-HF is the first heart failure outcomes trial with an SGLT2 inhibitor investigating
the treatment of heart failure in adults with HFrEF on top of standard of care (
which includes medicines such as angiotensin-converting enzyme [ACE] inhibitors,
angiotensin II receptor blockers [ARB], beta blockers, mineralocorticoid-receptor
antagonists [MRAs] and neprilysin inhibitors), in patients with and without type-
2 diabetes.

The full DAPA-HF trial results will be submitted for presentation at a forthcoming
medical meeting.

Farxiga is also being studied in patients with heart failure with preserved ejection
fraction (HFpEF) in the DELIVER and DETERMINE (HFrEF and HFpEF) trials.

**About DAPA-HF**

DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) is the
first heart failure trial with an SGLT2 inhibitor and morbidity and mortality outcomes
investigating the treatment of heart failure on top of standard of care, in a representative
patient population (NYHA II to IV) with and without type-2 diabetes. DAPA-HF is 
an international, multi-centre, parallel group, randomised, double-blind trial in
patients with heart failure and reduced ejection fraction (LVEF ≤ 40%), with and
without type-2 diabetes, designed to evaluate the effect of Farxiga 10mg, compared
with placebo, given once daily in addition to standard of care. The primary composite
outcome was time to a worsening heart failure event (hospitalisation or equivalent
event; i.e. an urgent heart failure visit), or cardiovascular death.

**About heart failure**

Heart failure (HF) is a life-threatening disease in which the heart cannot pump 
enough blood around the body.1 It affects approximately 64 million people worldwide(
half of which have a reduced ejection fraction) and is a chronic and degenerative
disease where half of patients will die within five years of diagnosis.2,3,4 HF 
remains as ‘malignant’ as some of the most common cancers in both men (prostate 
and bladder cancers) and women (breast cancers).5 It is the leading cause of hospitalisation
for those over the age of 65 and represents a significant clinical and economic 
burden.6

**About Farxiga**

Farxiga is a first-in-class, oral once-daily SGLT2 inhibitor indicated as both monotherapy
and as part of combination therapy to improve glycaemic control, with the additional
benefits of weight loss and blood-pressure reduction, as an adjunct to diet and 
exercise in adults with T2D. Farxiga has a robust programme of clinical trials that
includes more than 35 completed and ongoing Phase IIb/III trials in more than 35,000
patients, as well as more than 2.5 million patient-years’ experience.

**About the DapaCare Clinical Programme**

AstraZeneca is taking a holistic, patient-centric approach to disease management
by addressing the underlying morbidity, mortality and organ damage associated with
cardiovascular (CV), metabolic and renal diseases. Due to the interconnectivity 
of these diseases, AstraZeneca has developed the DapaCare clinical programme to 
explore the CV and renal profile of Farxiga in people with and without type-2 diabetes.
The clinical programme will enrol nearly 30,000 patients in randomised clinical 
trials and is supported by a multinational real-world evidence study. DapaCare will
generate data across a spectrum of people with established CV disease, CV risk factors
and varying stages of renal disease, both with and without type-2 diabetes, providing
healthcare providers with evidence needed to improve patient outcomes.

Farxiga is also being developed for patients with heart failure in the DELIVER (
HFpEF) and DETERMINE (HFrEF and HFpEF) trials, in addition to chronic kidney disease
in the DAPA-CKD trial. DapaCare underscores our commitment to following the science
by pursuing a holistic patient approach to address the multiple risk factors associated
with CV, renal and metabolic diseases.

**About AstraZeneca in heart failure**

AstraZeneca is committed to advancing science and clinical outcomes with Farxiga
in the treatment of people with HF. The company’s extensive clinical programme includes
several global Phase III trials (DAPA-HF, DELIVER and DETERMINE) focusing on distinct
and clinically important areas of HF research in order to provide comprehensive 
clinical evidence around the disease and address areas of high unmet need in HF.
AstraZeneca is also investing its efforts in compelling new science through early-
stage research of several potential medicines to address HF.

**About AstraZeneca in CVRM**

Cardiovascular, Renal & Metabolism (CVRM) together forms one of AstraZeneca’s three
therapy areas and is a key growth driver for the Company. By following the science
to understand more clearly the underlying links between the heart, kidneys and pancreas,
AstraZeneca is investing in a portfolio of medicines to protect organs and improve
outcomes by slowing disease progression, reducing risks and tackling co-morbidities.
The Company’s ambition is to modify or halt the natural course of CVRM diseases 
and potentially regenerate organs and restore function, by continuing to deliver
transformative science that improves treatment practices and cardiovascular health
for millions of patients worldwide.

**About AstraZeneca plc**

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription medicines, primarily
for the treatment of diseases in three therapy areas – Oncology, CVRM, and Respiratory.
AstraZeneca operates in over 100 countries and its innovative medicines are used
by millions of patients worldwide.

Share on:
